Fallbericht
B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series
Clinical Nephrology · 2025
DOI: 10.5414/cn111372 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Qinglian Wang und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Rituximab, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, B-Lymphocytes, Immunologic Factors.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
RituximabAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisB-LymphocytesImmunologic FactorsGlomerulonephritisHumansMaleFemaleMiddle AgedAgedRemission InductionTreatment OutcomeInduction Chemotherapy
Substanzen
RituximabImmunologic Factors
Zitieren
APA
Wang, Q., Wang, S., Liu, X., Cheng, F., & Xu, Y. (2025). B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series. Clinical Nephrology. https://doi.org/10.5414/cn111372
Vancouver
Wang Q, Wang S, Liu X, Cheng F, Xu Y. B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series. Clinical Nephrology. 2025. doi:10.5414/cn111372
BibTeX
@article{Wang2025,
author = {Wang, Qinglian and Wang, Simeng and Liu, Xiang and Cheng, Fajuan and Xu, Ying},
title = {B cell-driven reduced-dose rituximab as induction therapy for 2 patients with ANCA-associated renal vasculitis: A case series},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cn111372}
}
EUVIMED